Palvella Therapeutics Inc
PVLA
NASDAQ
Biotechnology
$156.13
USD
-0.42 (-0.27%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.24B
Volume 109.8K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-61.70M
TTM
— YoY
Operating Cash Flow
$-36.51M
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.1 | 3.6 | 4.2 | 5.5 | 8.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 9.3 | 10.2 | 11.3 | 14.9 | 21.4 |
Operating Income | -9.3 | -10.2 | -11.3 | -14.9 | -21.4 |
EBITDA | -9.3 | -10.2 | -11.3 | -14.9 | -21.4 |
Other Income / Expense | 1.1 | -0.3 | -0.2 | 0.1 | 1.8 |
Total Other Income / Expense | -0.2 | -1.2 | -1.4 | -0.9 | -0.5 |
Income Before Income Taxes | -9.5 | -11.3 | -12.7 | -15.8 | -21.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -9.5 | -11.3 | -12.7 | -15.8 | -21.9 |
Consolidated Net Income / Loss | -9.5 | -11.3 | -12.7 | -15.8 | -21.9 |
Net Income Attributable to Common Shareholders | -9.5 | -11.3 | -12.7 | -15.8 | -21.9 |
Basic EPS | -$0.86 | -$1.03 | -$1.07 | -$1.20 | -$1.52 |
Diluted EPS | -$0.86 | -$1.03 | -$1.07 | -$1.20 | -$1.52 |
Basic Shares Outstanding | 11.1M | 11.1M | 11.9M | 13.1M | 14.4M |
Diluted Shares Outstanding | 11.1M | 11.1M | 11.9M | 13.1M | 14.4M |